A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Investigator(s):
Gary Schiller, M.D.;
Organization:
UCLA
NCT Number:
Disease Name:
Beta-Thalassemia
Disease Category:
Trial Phases:
Phase 1/2
Trial Status:
Active, Not Recruiting
Trial Contact:
Bruck Habtemariam
(310) 794-0242
BHabtemariam@mednet.ucla.edu